Drug manufacturer Most Active: Merck & Co. (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Raptor Pharmaceutical (NASDAQ:RPTP)

Bristol-Myers Squibb Co (NYSE:BMY)’s ipilimumab, or Yervoy as it’s commercially known, was dubbed the skin cancer ‘wonder’ drug by the media when it was licensed for use in the UK in 2011. Bristol-Myers Squibb Co (NYSE:BMY) dropped -0.33 percent to $54.00 Friday on volume of 8.05million shares. The intra-day range of the stock was $53.88 to $54.44. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $89.11billion.

Senior Analyst Glenn Novarro of RBC Capital Markets foresees Johnson & Johnson (NYSE:JNJ) experiencing strong pharmaceutical growth and a recovery of consumer sales growth in 2014, followed by outperformance in operating margins in 2015. Johnson & Johnson (NYSE:JNJ)’s stock on Mar 14, 2014 reported a decrease of -0.20% to the closing price of $92.81. Its fifty two weeks range is $78.50-$95.99. The total market capitalization recorded $262.50billion. The overall volume in the last trading session was 7.34million shares. In its share capital, JNJ has 2.82billion outstanding shares.

MDMA — or 3,4-methylenedioxy-N-methamphetamine — was first synthesized a century ago by chemists at Merck & Co. Inc. (NYSE:MRK), which patented it as a precursor to a blood-clotting medication. Merck & Co. Inc. (NYSE:MRK) stock performance was -0.16% in last session and finished the day at $55.70. Traded volume was 12.12million shares in the last session and the average volume of the stock remained 12.35million shares. The beta of the stock remained 0.32. Merck & Co., Inc. (NYSE:MRK) insider ownership is 0.03%.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) plummeted nearly 23 percent today after the biotechnology company posted a non-GAAP loss of $0.19 per share for the fourth quarter that was wider than a loss of $0.16 per share estimated by analysts. On Friday, shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) dropped -23.94% to close the day at $11.25. Company monthly performance is recorded as -27.37%. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) quarterly revenue growth is -21.27%.